Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Gemma Austin"'
Autor:
Gemma Austin, Laura Scott, Laura J. Bonnett, Christopher Law, Jane F. Apperley, Claire M. Lucas, Ammar A. Basabrain, Richard E. Clark, Sandra Loaiza, Alison K. Holcroft, Alexandra D. Parry
Publikováno v:
Cancers, Vol 13, Iss 2155, p 2155 (2021)
Cancers
Volume 13
Issue 9
CANCERS
Cancers
Volume 13
Issue 9
CANCERS
Background: It would be clinically useful to prospectively identify the risk of disease progression in chronic myeloid leukaemia (CML). Overexpression of cancerous inhibitor of protein phosphatase 2A (PP2A) (CIP2A) protein is an adverse prognostic in
Autor:
Mark Zorman, Claire Hobbs, Carol Thurgood, R.A. Watson, Nick Coupe, Philip S Webb, Miranda Payne, Gemma Austin
Publikováno v:
Neuro-Oncology. 23:iv16-iv16
Aims Melanoma brain metastases (MBM) are a common presentation to the neuro-oncology MDT. Stereotactic radiosurgery (SRS) is a highly effective treatment for cerebral metastases, with at least 70% control rates of individual metastases,[1] whilst imm
Autor:
Munir Pirmohamed, Sandra Loaiza, Richard E. Clark, Ana E. Rodríguez-Vicente, Gemma Austin, Andrea Davies, Letizia Foroni
Publikováno v:
Scientific Reports
Scientific Reports, Vol 10, Iss 1, Pp 1-9 (2020)
Scientific reports
Digital.CSIC. Repositorio Institucional del CSIC
instname
Scientific Reports, Vol 10, Iss 1, Pp 1-9 (2020)
Scientific reports
Digital.CSIC. Repositorio Institucional del CSIC
instname
Tyrosine kinase inhibitors (TKIs), the treatment of choice for chronic myeloid leukaemia (CML), can cause lower gastrointestinal (GI) toxicity which is manifested as diarrhoea. The mechanisms are not fully understood. The enteroendocrine signalling c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d921e866cc3711027543ac4d7a44d09
http://hdl.handle.net/10261/222988
http://hdl.handle.net/10261/222988
Autor:
Karen Dunn, James Austin, Claire M. Lucas, Gemma Austin, Richard E. Clark, Rosalind E. Jenkins, Mark A. Glenn, Laura Scott
Publikováno v:
BIOCHEMICAL JOURNAL
Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an adverse biomarker across many malignancies. Using K562 cells engineered to have high or low CIP2A expression, we show that high CIP2A levels significantly bias cellular energy production tow
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae03d8d0624e25e6e862fce2888a1f1d
http://livrepository.liverpool.ac.uk/3051547/1/BCJ20190121.full.pdf
http://livrepository.liverpool.ac.uk/3051547/1/BCJ20190121.full.pdf
Autor:
Katy Knight, Earnest Heartin, Anthony Carter, Stephen E. Christmas, Gemma Austin, Letizia Foroni, Richard E. Clark, Joanne Bell, David Watson, Fotios Polydoros
Publikováno v:
BRITISH JOURNAL OF HAEMATOLOGY
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78f696ec3ff863d3566686cb9e2f5302
Autor:
Triantafilos Liloglou, Tessa L. Holyoake, Munir Pirmohamed, George Xinarianos, Sudeep Pushpakom, Jieying-Eunice Zhang, Richard E. Clark, Letizia Foroni, Lihui Wang, Gemma Austin, Andrea L. Jorgensen, Martin C. Müller, Andrea Davies, Athina Giannoudis, Panagiotis D. Kottaridis
Publikováno v:
Blood. 121:628-637
Although the prognosis of chronic myeloid leukemia (CML) patients treated with imatinib is good, many fail to develop an optimal response or lose one. This heterogeneity could be attributed to the presence of human organic cation transporter-1 (hOCT1
Publikováno v:
European journal of haematology. 94(1)
The expression and activity of the uptake transporter human organic cation transporter 1 (hOCT1; SLC22A1) is an independent predictor of response to imatinib treatment in patients with chronic myeloid leukaemia (CML). We have recently shown that pero
Autor:
Andrea Davies, Lihui Wang, Tessa L. Holyoake, Panagiotis D. Kottaridis, Martin C. Müller, Richard E. Clark, Jieying Eunice Zhang, Athina Giannoudis, Munir Pirmohamed, Letizia Foroni, Gemma Austin
Publikováno v:
Clinical pharmacology and therapeutics. 96(6)
Approximately 40% of patients with chronic myeloid leukemia (CML) receiving imatinib fail treatment. There is an increased risk of CML in subjects with (i) deletions of genes encoding glutathione-S-transferase (GST)-θ1 (GSTT1) and -μ1, (GSTM1) and
Publikováno v:
Experimental hematology. 40(10)
Low pretreatment expression of the imatinib uptake transporter human organic cation transporter 1 (hOCT1) is associated with inferior complete cytogenetic response rates, progression-free survival, and overall survival in imatinib-treated chronic mye